Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study.

Noyes K, Bajorska A, Chappel A, Schwid SR, Mehta LR, Weinstock-Guttman B, Holloway RG, Dick AW.

Neurology. 2011 Jul 26;77(4):355-63. doi: 10.1212/WNL.0b013e3182270402. Epub 2011 Jul 20.

2.

Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis.

Krupp LB, Christodoulou C, Melville P, Scherl WF, Pai LY, Muenz LR, He D, Benedict RH, Goodman A, Rizvi S, Schwid SR, Weinstock-Guttman B, Westervelt HJ, Wishart H.

Neurology. 2011 Apr 26;76(17):1500-7. doi: 10.1212/WNL.0b013e318218107a.

3.

Broadening the spectrum of controls for skin biopsy in painful neuropathies.

Herrmann DN, O'Connor AB, Schwid SR, Da Y, Goodman AD, Rafferty J, Donahue S, Dworkin RH.

Muscle Nerve. 2010 Sep;42(3):436-8. doi: 10.1002/mus.21747.

PMID:
20806398
4.

Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease.

Schwid SR, Bausch J, Oakes D, Schuchter L, Tanner C, Forrest M, Lang AE, Shoulson I; PSG PRECEPT Investigators, Shoulson I, Hyson C, Oakes D, Flagg E, Rudolph A, Kieburtz K, Lang A, Fahn S, Gauger L, Goetz C.

Mov Disord. 2010 Sep 15;25(12):1801-8. doi: 10.1002/mds.23006.

PMID:
20669311
5.

A randomized trial of memantine as treatment for spasticity in multiple sclerosis.

Mehta LR, McDermott MP, Goodman AD, Schwid SR.

Mult Scler. 2010 Feb;16(2):248-51. doi: 10.1177/1352458509355462. Epub 2009 Dec 22.

PMID:
20028712
6.

A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts.

Marras C, Lang AE, Eberly SW, Oakes D, Fahn S, Schwid SR, Hyson C, Shoulson I; Parkinson Study Group DATATOP and PRECEPT investigators.

Mov Disord. 2009 Dec 15;24(16):2370-8. doi: 10.1002/mds.22828.

PMID:
19908310
7.

Urate as a predictor of the rate of clinical decline in Parkinson disease.

Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, Marras C, Kieburtz K, Rudolph A, Bogdanov MB, Schwid SR, Tennis M, Tanner CM, Beal MF, Lang AE, Oakes D, Fahn S, Shoulson I, Schwarzschild MA; Parkinson Study Group DATATOP Investigators.

Arch Neurol. 2009 Dec;66(12):1460-8. doi: 10.1001/archneurol.2009.247.

8.

Assessing disability progression with the Multiple Sclerosis Functional Composite.

Rudick RA, Polman CH, Cohen JA, Walton MK, Miller AE, Confavreux C, Lublin FD, Hutchinson M, O'Connor PW, Schwid SR, Balcer LJ, Lynn F, Panzara MA, Sandrock AW.

Mult Scler. 2009 Aug;15(8):984-97. doi: 10.1177/1352458509106212.

PMID:
19667023
9.

Proof of concept studies for tissue-protective agents in multiple sclerosis.

Mehta LR, Schwid SR, Arnold DL, Cutter GR, Aradhye S, Balcer LJ, Calabresi PA, Cohen JA, Cole PE, Glanzman R, Goelz S, Inglese M, Kapoor R, Kappos L, Kreitman R, Lublin FD, Mann A, Marrie RA, O'Looney P, Polman CH, Ravina BM, Reingold SC, Richert JR, Sandrock AW, Waubant E.

Mult Scler. 2009 May;15(5):542-6. doi: 10.1177/1352458508101939. Review.

PMID:
19389749
10.

Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.

Goodman AD, Brown TR, Krupp LB, Schapiro RT, Schwid SR, Cohen R, Marinucci LN, Blight AR; Fampridine MS-F203 Investigators.

Lancet. 2009 Feb 28;373(9665):732-8. doi: 10.1016/S0140-6736(09)60442-6.

PMID:
19249634
11.

Polyunsaturated fatty acids and their potential therapeutic role in multiple sclerosis.

Mehta LR, Dworkin RH, Schwid SR.

Nat Clin Pract Neurol. 2009 Feb;5(2):82-92. doi: 10.1038/ncpneuro1009. Review.

PMID:
19194388
12.

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.

Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, Stubinski B, Uitdehaag B; REGARD study group.

Lancet Neurol. 2008 Oct;7(10):903-14. doi: 10.1016/S1474-4422(08)70200-X. Epub 2008 Sep 11.

PMID:
18789766
13.

Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson disease.

White WB, Salzman P, Schwid SR; Parkinson's Rasagiline: Efficacy and Safety in the Treatment of Off Parkinson Study Group.

Hypertension. 2008 Sep;52(3):587-93. doi: 10.1161/HYPERTENSIONAHA.108.115873. Epub 2008 Aug 4.

PMID:
18678789
14.

Dose comparison trial of sustained-release fampridine in multiple sclerosis.

Goodman AD, Brown TR, Cohen JA, Krupp LB, Schapiro R, Schwid SR, Cohen R, Marinucci LN, Blight AR; Fampridine MS-F202 Study Group.

Neurology. 2008 Oct 7;71(15):1134-41. doi: 10.1212/01.wnl.0000326213.89576.0e. Epub 2008 Jul 30.

PMID:
18672472
15.

Quantitative risk-benefit analysis of natalizumab.

Thompson JP, Noyes K, Dorsey ER, Schwid SR, Holloway RG.

Neurology. 2008 Jul 29;71(5):357-64. doi: 10.1212/01.wnl.0000319648.65173.7a.

16.

Serum urate as a predictor of clinical and radiographic progression in Parkinson disease.

Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, Shoulson I, Ascherio A; Parkinson Study Group PRECEPT Investigators, Hyson C, Gorbold E, Rudolph A, Kieburtz K, Fahn S, Gauger L, Goetz C, Seibyl J, Forrest M, Ondrasik J.

Arch Neurol. 2008 Jun;65(6):716-23. doi: 10.1001/archneur.2008.65.6.nct70003. Epub 2008 Apr 14.

17.

Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment.

Polman CH, Reingold SC, Barkhof F, Calabresi PA, Clanet M, Cohen JA, Cutter GR, Freedman MS, Kappos L, Lublin FD, McFarland HF, Metz LM, Miller AE, Montalban X, O'Connor PW, Panitch H, Richert JR, Petkau J, Schwid SR, Sormani MP, Thompson AJ, Weinshenker BG, Wolinsky JS.

Neurology. 2008 Mar 25;70(13 Pt 2):1134-40. doi: 10.1212/01.wnl.0000306410.84794.4d.

PMID:
18362273
18.

Neuromyelitis optica spectrum disorder in a patient with systemic lupus erythematosus and anti-phospholipid antibody syndrome.

Mehta LR, Samuelsson MK, Kleiner AK, Goodman AD, Anolik JH, Looney RJ, Schwid SR.

Mult Scler. 2008 Apr;14(3):425-7. doi: 10.1177/1352458507084107. Epub 2008 Jan 21.

PMID:
18208886
20.

Comparison of mobility device delivery within Department of Veterans Affairs for individuals with multiple sclerosis versus spinal cord injury.

Ambrosio F, Boninger ML, Fitzgerald SG, Hubbard SL, Schwid SR, Cooper RA.

J Rehabil Res Dev. 2007;44(5):693-701.

21.

Pain associated with multiple sclerosis: systematic review and proposed classification.

O'Connor AB, Schwid SR, Herrmann DN, Markman JD, Dworkin RH.

Pain. 2008 Jul;137(1):96-111. Epub 2007 Oct 24. Review.

PMID:
17928147
22.

Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis.

Dorsey ER, Thompson JP, Noyes K, Dick AW, Holloway RG, Schwid SR.

Neurology. 2007 May 1;68(18):1524-8.

PMID:
17470756
23.

Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial.

Schwid SR, Goodman AD, Weinstein A, McDermott MP, Johnson KP; Copaxone Study Group.

J Neurol Sci. 2007 Apr 15;255(1-2):57-63. Epub 2007 Feb 28.

PMID:
17331542
24.

Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline.

deMarcaida JA, Schwid SR, White WB, Blindauer K, Fahn S, Kieburtz K, Stern M, Shoulson I; Parkinson Study Group TEMPO; PRESTO Tyramine Substudy Investigators and Coordinators.

Mov Disord. 2006 Oct;21(10):1716-21.

PMID:
16856145
25.

Safety of rasagiline in elderly patients with Parkinson disease.

Goetz CG, Schwid SR, Eberly SW, Oakes D, Shoulson I; Parkinson Study Group TEMPO and PRESTO Investigators.

Neurology. 2006 May 9;66(9):1427-9.

PMID:
16682679
26.

Futility studies: spending a little to save a lot.

Schwid SR, Cutter GR.

Neurology. 2006 Mar 14;66(5):626-7. No abstract available.

PMID:
16534098
27.

Immune response to influenza vaccine is maintained in patients with multiple sclerosis receiving interferon beta-1a.

Schwid SR, Decker MD, Lopez-Bresnahan M; Rebif-Influenza Vaccine Study Investigators.

Neurology. 2005 Dec 27;65(12):1964-6.

PMID:
16380621
28.

Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study.

Schwid SR, Thorpe J, Sharief M, Sandberg-Wollheim M, Rammohan K, Wendt J, Panitch H, Goodin D, Li D, Chang P, Francis G; EVIDENCE (Evidence of Interferon Dose-Response: European North American Comparative Efficacy) Study Group; University of British Columbia MS/MRI Research Group.

Arch Neurol. 2005 May;62(5):785-92.

PMID:
15883267
29.

Treating fatigue in patients with MS: one step forward, one step back.

Schwid SR, Murray TJ.

Neurology. 2005 Apr 12;64(7):1111-2. No abstract available.

PMID:
15824329
30.

Cognitive fatigue during a test requiring sustained attention: a pilot study.

Schwid SR, Tyler CM, Scheid EA, Weinstein A, Goodman AD, McDermott MP.

Mult Scler. 2003 Oct;9(5):503-8.

PMID:
14582777
31.

A randomized controlled study of the acute and chronic effects of cooling therapy for MS.

Schwid SR, Petrie MD, Murray R, Leitch J, Bowen J, Alquist A, Pelligrino R, Roberts A, Harper-Bennie J, Milan MD, Guisado R, Luna B, Montgomery L, Lamparter R, Ku YT, Lee H, Goldwater D, Cutter G, Webbon B; NASA/MS Cooling Study Group.

Neurology. 2003 Jun 24;60(12):1955-60.

PMID:
12821739
32.

Multiple sclerosis, depression, and the risk of suicide.

Caine ED, Schwid SR.

Neurology. 2002 Sep 10;59(5):662-3. No abstract available.

PMID:
12221154
33.

Fatigue in multiple sclerosis: current understanding and future directions.

Schwid SR, Covington M, Segal BM, Goodman AD.

J Rehabil Res Dev. 2002 Mar-Apr;39(2):211-24. Review.

34.

Quantitative functional measures in MS: what is a reliable change?

Schwid SR, Goodman AD, McDermott MP, Bever CF, Cook SD.

Neurology. 2002 Apr 23;58(8):1294-6.

PMID:
11971105
35.

The cost of delaying treatment in multiple sclerosis: what is lost is not regained.

Schwid SR, Bever CT Jr.

Neurology. 2001 Jun 26;56(12):1620. No abstract available.

PMID:
11425925
36.

Are quantitative functional measures more sensitive to worsening MS than traditional measures?

Schwid SR, Goodman AD, Apatoff BR, Coyle PK, Jacobs LD, Krupp LB, Miller AE, Wende KE, Brownscheidle CM, New York State Multiple Sclero.

Neurology. 2000 Dec 26;55(12):1901-3.

PMID:
11134392
37.

Lessons from linomide: a failed trial, but not a failure.

Schwid SR, Trotter JL.

Neurology. 2000 May 9;54(9):1716-7. No abstract available.

PMID:
10802772
38.

Quantitative assessment of motor fatigue and strength in MS.

Schwid SR, Thornton CA, Pandya S, Manzur KL, Sanjak M, Petrie MD, McDermott MP, Goodman AD.

Neurology. 1999 Sep 11;53(4):743-50.

PMID:
10489035
39.

Targeting immunotherapy in multiple sclerosis: a near hit and a clear miss.

Schwid SR, Noseworthy JH.

Neurology. 1999 Aug 11;53(3):444-5. No abstract available.

PMID:
10449101
40.

Therapy of relapsing multiple sclerosis. Treatment approaches for nonresponders.

Cohen JA, Carter JL, Kinkel RP, Schwid SR.

J Neuroimmunol. 1999 Jul 1;98(1):29-36. Review.

PMID:
10426359
41.

Neuropsychologic status in multiple sclerosis after treatment with glatiramer.

Weinstein A, Schwid SR, Schiffer RB, McDermott MP, Giang DW, Goodman AD.

Arch Neurol. 1999 Mar;56(3):319-24. Erratum in: Arch Neurol. 2004 Aug;61(8):1284. Schwid SI [corrected to Schwid SR].

PMID:
10190822
42.

The measurement of ambulatory impairment in multiple sclerosis.

Schwid SR, Goodman AD, Mattson DH, Mihai C, Donohoe KM, Petrie MD, Scheid EA, Dudman JT, McDermott MP.

Neurology. 1997 Nov;49(5):1419-24.

PMID:
9371932
43.

Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon beta-1b.

Schwid SR, Goodman AD, Mattson DH.

Arch Neurol. 1997 Sep;54(9):1169-90.

PMID:
9311363
44.

Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis.

Schwid SR, Petrie MD, McDermott MP, Tierney DS, Mason DH, Goodman AD.

Neurology. 1997 Apr;48(4):817-21.

PMID:
9109861
45.

Sporadic corticosteroid pulses and osteoporosis in multiple sclerosis.

Schwid SR, Goodman AD, Puzas JE, McDermott MP, Mattson DH.

Arch Neurol. 1996 Aug;53(8):753-7.

PMID:
8759981
46.

Nicotine effects on body weight: a regulatory perspective.

Schwid SR, Hirvonen MD, Keesey RE.

Am J Clin Nutr. 1992 Apr;55(4):878-84.

PMID:
1550071

Supplemental Content

Loading ...
Support Center